Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $1.53 billion versus the consensus estimate of $1.5 billion.

GUIDANCE:

Edwards Lifesciences sees FY2023 EPS of $2.50-$2.60, versus the consensus of $2.55. Edwards Lifesciences sees FY2023 revenue of $5.9-6.1 million, versus the consensus of $5.96 million.

Edwards Lifesciences sees Q3 2023 EPS of $0.55-$0.61, versus the consensus of $0.63. Edwards Lifesciences sees Q3 2023 revenue of $1.44-1.52 million, versus the consensus of $1.47 million.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.